For Healthcare Providers

A patient support resource built on the evidence your patients need.

GabaDown is a patient advocacy resource — not a clinical service. Based on the patient's intake and published deprescribing guidelines, GabaDown produces a draft taper framework the patient brings to you for review and approval. You stay the clinical decision-maker. GabaDown does the structural work a 15-minute appointment doesn't have time for.

Works alongside your care Never prescribes or diagnoses Requires your supervision Available US & Canada Not a clinical provider Not a substitute for your role

Scope

What GabaDown is — and isn't

We are clear with every patient about the boundaries of this resource before they engage. Your clinical role is not replaced or diminished.

GabaDown is

A personalized patient education and planning resource
A draft taper framework produced from the patient's intake and published deprescribing guidelines — formatted for your review and approval
Between-appointment support via an AI assistant trained on the patient's specific plan
A daily tracking tool that generates data the patient can bring to their appointments
Supplement information grounded in published research, with explicit pharmacist-consult reminders
A patient advocacy and motivation resource for the long duration of a supervised taper
A healthcare team summary — a one-page document formatted for your review, showing the draft taper framework and what the patient is tracking

GabaDown is not

A clinical or medical service
A prescriber — of any kind, including supplements
A replacement for your supervision or pharmacist involvement
An emergency service — all emergencies are directed to the patient's doctor and emergency services
A substitute for your clinical judgment
Designed for patients who do not have a doctor's support for their reduction plan

Evidence base

The research this resource is built on

GabaDown draws on peer-reviewed evidence for its taper frameworks and supplement information. The key publications informing this resource:

Publication	Relevance
Horowitz MA & Taylor DM. The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs. Wiley-Blackwell, 2024.	First major clinical guideline to address gabapentinoids specifically. Basis for hyperbolic tapering concepts referenced in patient journals — the position that receptor occupancy follows a hyperbolic curve, so reduction steps should get smaller as dose decreases.
Mersfelder TL & Nichols WH. Gabapentin: Abuse, Dependence, and Withdrawal. Ann Pharmacother, 2016.	Established that withdrawal symptoms are more likely at daily doses over 1,800mg — foundational to GabaDown's focus on long-term high-dose users specifically.
JAGS case study, 2025. Patient-directed gabapentin taper in an older adult.	Documents improved mental clarity, mobility, and medication burden following a patient-initiated, supervised reduction — directly mirrors the GabaDown client profile.
McDonald EG et al. Patient empowerment brochures to increase gabapentinoid deprescribing: the GABA-WHY trial. CMAJ Open, 2022.	Showed patient education materials doubled gabapentinoid deprescribing rates (21.1% vs 9.9%). GabaDown is a deeper, personalized version of this kind of patient education intervention.
Strahan AE et al. Trends in Dispensed Gabapentin Prescriptions in the United States, 2010 to 2024. Ann Intern Med, 2025.	Documents the scale of long-term gabapentin use and rising prescribing rates — contextualising the patient population GabaDown serves.

What your patient receives

The complete GabaDown system

Each journal is built from a detailed intake questionnaire and delivered within 7 days. Everything is tailored to the patient's starting dose, history, and the method you've recommended.

Draft taper framework + healthcare team summary

A structured phase-by-phase reduction schedule built from the patient's intake and published guidelines (Maudsley 2024, Horowitz & Taylor). Formatted as a one-page summary the patient brings to you for review. You approve, adjust, or adopt it — it then becomes the plan the journal is built around.

Daily tracking log

Pain, sleep, mood, energy, blood pressure, supplements — builds a dataset the patient brings to every appointment with you.

Supplement information

Evidence-referenced overview of commonly used supplements during gabapentin reduction. Patients are instructed to confirm everything with their pharmacist before use.

AI Plan Assistant

Answers questions about the patient's specific journal — not a general health chatbot. Cannot diagnose, prescribe, or handle emergencies. Directs all emergencies to the patient's doctor.

Patient advocacy guide

How to communicate effectively with their care team — including how to raise concerns, what to track, and how to ask for hold periods when needed.

Milestone structure

A reward and motivation system for each reduction milestone — important for a process that can last 12–18 months with no external reinforcement.

Referral process

How a referral works

Three steps. No forms on your end. No clinical liability — GabaDown is a patient-initiated resource that works alongside your care.

1

You mention GabaDown to your patient

Share gabadown.com or this page. The patient reviews the resource and decides whether it's right for them. No forms to fill out on your end, no clinical liability to manage — GabaDown is a patient-initiated resource.
2

Patient completes their intake and receives their draft framework

The patient completes a detailed intake questionnaire about their current dose, their history, their goals, and your general direction on reduction. GabaDown produces a draft taper framework based on published deprescribing guidelines — along with a one-page healthcare team summary formatted for your review. The patient brings this to their next appointment with you.
3

Patient arrives at appointments with better data

The patient arrives with a one-page healthcare team summary showing their draft framework, their tracking data, and their progress. You review the draft, adjust if needed, and approve it at the first appointment — then see real tracking data at every appointment thereafter. You stay the clinical decision-maker; GabaDown provides the structure between appointments.

Get in touch

Questions, referrals, or collaboration

If you have questions about GabaDown's clinical framing, want to discuss a specific patient situation, or are interested in a deeper conversation about the resource — reach out directly.

Contact GabaDown

Email is the best way to reach us. We respond to all provider enquiries within 24 hours. If you want to share GabaDown with a patient directly, gabadown.com is the patient-facing entry point.

hello@gabadown.com

GabaDown is available to patients across the United States and Canada. Pricing is in USD. No clinical records or referral forms are required — patients engage directly and self-identify as having a prescribing physician's support for their reduction plan.

Clinical disclaimer: GabaDown is a patient advocacy and personal support resource. It is not a medical service, does not employ clinicians, and nothing on this website or in any GabaDown journal constitutes medical advice, diagnosis, or treatment. GabaDown requires that all clients have a doctor who is aware of and supportive of their reduction plan before beginning. All taper decisions remain the responsibility of the prescribing physician and pharmacist. GabaDown does not advocate for any specific tapering method and follows whatever approach the prescribing physician recommends.

For clinical emergencies, patients are directed to their doctor and local emergency services. GabaDown is not an emergency service.